Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ therapeutic use
Betacoronavirus
/ drug effects
COVID-19
Case-Control Studies
Comorbidity
Coronavirus Infections
/ drug therapy
Critical Illness
/ epidemiology
Female
France
/ epidemiology
Humans
Intensive Care Units
/ statistics & numerical data
Male
Middle Aged
Mortality
Pandemics
Patient Admission
/ statistics & numerical data
Pneumonia, Viral
/ drug therapy
Retrospective Studies
SARS-CoV-2
Severity of Illness Index
Treatment Outcome
Young Adult
COVID-19
Intensive care unit
Mortality
SARS-CoV-2
Tocilizumab
Journal
Medecine et maladies infectieuses
ISSN: 1769-6690
Titre abrégé: Med Mal Infect
Pays: France
ID NLM: 0311416
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
29
04
2020
accepted:
04
05
2020
pubmed:
11
5
2020
medline:
13
8
2020
entrez:
11
5
2020
Statut:
ppublish
Résumé
No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions. Patients with TCZ (n=20) had a higher Charlson comorbidity index (5.3 [±2.4] vs 3.4 [±2.6], P=0.014), presented with more severe forms (higher level of oxygen therapy at 13L/min vs 6L/min, P<0.001), and had poorer biological findings (severe lymphopenia: 676/mm Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.
Identifiants
pubmed: 32387320
pii: S0399-077X(20)30129-3
doi: 10.1016/j.medmal.2020.05.001
pmc: PMC7202806
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
tocilizumab
I031V2H011
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
397-400Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Références
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Ann Oncol. 2020 Jul;31(7):961-964
pubmed: 32247642
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Lancet. 2020 Mar 28;395(10229):1014-1015
pubmed: 32197108
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Ann Rheum Dis. 2020 May;79(5):668-669
pubmed: 32241792
J Transl Med. 2020 Apr 14;18(1):164
pubmed: 32290839
Blood Adv. 2020 Apr 14;4(7):1307-1310
pubmed: 32243501